International pharmaceutical company Ferrer has announcing today the signing of a distribution agreement with United Therapeutics Corporation for Tyvaso (treprostinil) inhalation solution. The product is a pharmaceutical drug-device for the treatment of WHO Group pulmonary hypertension, associated with interstitial lung disease (PH-ILD).
Mario Rovirosa, Ferrer’s CEO, said: “This is an important milestone for Ferrer, a B Corp company. As an organisation, we aim to deliver the best possible solutions to underserved patients around the globe by promoting a new way of doing business and approaching the world.”
Under the agreement, Ferrer has been appointed as the exclusive distributor - outside of the US, Canada, Japan, China and Israel - to commercialise Tyvaso.
“We’re proud of our strong and lasting relationship with Ferrer, and this distribution agreement has the potential to bring Tyvaso to PH-ILD patients in need worldwide, who currently have no other treatment options,” said Michael Benkowitz, President and COO, United Therapeutics. “Having recently converted into a public benefit corporation ourselves, we applaud and share Ferrer’s patient-driven mission – underscored by its recent B Corp certification.”
The agreement leverages Ferrer’s capabilities in pulmonary vascular and interstitial lung diseases and underscores the companies’ commitment to expanding global access to treprostinil inhalation solution for the treatment of PH-ILD, they say.
The distributor is a long-term partner of United Therapeutics, responsible for providing global access to Remodulin for the treatment of pulmonary arterial hypertension.
“We’ve found Ferrer to be an excellent partner for the distribution of our treprostinil-based products around the world and are thrilled to expand our collaboration. Without Ferrer, patients outside of our core markets would not have access to these life-sustaining therapies.” commented Beth Rhodes, VP, Global Supply Chain and Alliance Management, United Therapeutics.
Ferrer is working with health authorities to determine the appropriate regulatory pathway to obtain approval for this product (currently only authorised in the US) in other territories.